A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Exclusion Criteria

• •1. Cognitive impairment due to other medical or neurological factors (non-AD).
• •2. History of stroke or transient ischemic attack, seizures, or other unexplained loss of consciousness within the past 1 year.
• •3. Any psychiatric diagnosis that may interfere with the subject's cognitive assessment.
• •4. Inability to tolerate MRI examination or have contraindications to MRI examination.
• •8\. The subject is suicidal according to the investigator's judgment or has committed suicidal behaviour within 6 months prior to the screening period.
• •9\. Severe visual or hearing impairment, unable to cooperate in the scale examination.
• •10\. Patients suspected to be allergic to Aβ antibody drugs and their excipients.
• •11\. Women who are pregnant, or women of childbearing age with positive pregnancy test results or are lactating.
• •12\. History of drug abuse and/or drug addiction within 1 year prior to screening.
• •13 Use of dual antiplatelet or anticoagulant drugs within 3 months prior to the randomization period or planned during the trial.
• •14.Have had prior treatment with an anti-amyloid immunotherapy within 1 year prior to randomization.
• •15\. Those who have participated in a clinical trial of any drug or medical device within 3 months prior to screening.
• •16\. Investigators and site-related personnel or other persons directly involved in the implementation of the protocol.
• •17\. Other unspecified reasons that, in the opinion of the investigator or sponsor, make the subject unsuitable for enrolment.